Dr. Guillermo Amescua, MD

Dr. Amescua practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Amescua's NPI, 1376734095, was assigned on August 7, 2007. Dr. Amescua graduated from Escuela de Medicina Ignacio A. Santos in 2004. Dr. Amescua's Pennsylvania license number on file is MT191818.

Dr. Amescua's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Amescua's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Amescua practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Amescua's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Amescua is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Amescua's licenses on file in 3 states: Pennsylvania, Florida and New Mexico.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, cold sores or genital herpes, conjunctivitis, dry eye, eyelid inflammation and glaucoma among the conditions Dr. Amescua treats.

CMS data shows 788 Medicare services from Dr. Amescua across 9 procedure codes in 2024, for 494 Medicare patients. Medicare paid $113,367 for them.

CMS counts 494 Medicare patients who saw Dr. Amescua in 2024. The largest group is 75 to 84, with 235 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 21% are also on Medicaid. Their average risk score is 1.30, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Amescua's median patient age at 75, with 60% women.

In 2024, Dr. Amescua wrote 1,942 Medicare Part D claims for 477 patients. 58% of them were for generic drugs. CMS names the drug for 1,813 of them, across 21 drugs with 11 or more claims each, at $103,138 in total drug cost. In 2023, CMS named 1,940 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Amescua for performance year 2024, reported as part of a group. Dr. Amescua accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Amescua as offering telehealth. CMS counts 205 procedures of cataract surgery by Dr. Amescua, more than 84% of the clinicians it reports for that procedure.

Dmand AI links 91 papers to Dr. Amescua, published from 2009 to 2025. 2024 was the busiest year, with 13. The most frequent topics are Cornea, Keratitis and Rose Bengal. Dr. Amescua has published most often in Cornea. Dr. Amescua's most frequent co-authors are Alejandro Arboleda, Harry W. Flynn, MD and Anat Galor, MD.

Dmand AI links Dr. Amescua to 1 clinical trial.

CMS Open Payments shows 156 general payments to Dr. Amescua from 28 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 70% of the total. W. L. Gore & Associates, Inc. paid the most, $31,010.

Dmand AI lists 4 awards for Dr. Amescua, most recently Dr. José Belmonte Martinez Lecture in 2022.

Dr. Amescua graduated from Escuela de Medicina Ignacio A. Santos in 2004. Dr. Amescua is a member of AAO.

Dr. Amescua is in network with 10 carriers, including Elevance, Aetna and United Healthcare. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.